About InVivoMAb polyclonal goat IgG The polyclonal goat IgG is purified from goat serum. It is ideal for use as a non-reactive control IgG for goat IgG antibodies in most in vivo and in vitro applications. InVivoMAb polyclonal goat IgG Specifications IsotypeGoat IgG Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<2EU/mg (<0.002EU/μg) Determined by LAL gel clotting assay Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from goat serum PurificationProtein G RRIDAB_10949067 Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze. Application ReferencesInVivoMAb polyclonal goat IgG (CLONE: Polyclonal)Carretero, R., et al (2015). "Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells" Nat Immunol 16(6): 609-617. PubMedTumor-associated eosinophilia is frequently observed in cancer. However, despite numerous studies of patients with cancer and mouse models of cancer, it has remained uncertain if eosinophils contribute to tumor immunity or are mere bystander cells. Here we report that activated eosinophils were essential for tumor rejection in the presence of tumor-specific CD8(+) T cells. Tumor-homing eosinophils secreted chemoattractants that guided T cells into the tumor, which resulted in tumor eradication and survival. Activated eosinophils initiated substantial changes in the tumor microenvironment, including macrophage polarization and normalization of the tumor vasculature, which are known to promote tumor rejection. Thus, our study presents a new concept for eosinophils in cancer that may lead to novel therapeutic strategies.
